-
NEWS RELEASE
Introduction of the paper using our UUO model
2022.04.16
We would like to introduce a paper published by our client using Chronic kidney disease model.
-
NEWS RELEASE
2022.04.01
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis.
-
NEWS RELEASE
Drug efficacy studies using multiple mouse models to replicate human disease.
2022.03.16
To date, numerous clinical trials have been conducted using existing and newly developed drugs in the field of NASH.
-
NEWS RELEASE
The comparison of NASH-HCC and other HCC models
2022.03.11
Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020.
-
PUBLICATION
Drug efficacy study in NASH mouse model
2022.02.23
We would like to introduce a paper published by our client using our non-alcoholic steatohepatitis (NASH) model. (Murakami et al., Cells., 2022).
-
PUBLICATION
Published papers with IPF model
2022.02.10
We would like to share with you some examples of studies that our clients have often asked us about using the IPF model.
-
UPDATE
Why is Chronic Kidney Disease so hard to research?
2022.01.27
Between 9 - 12% of the worlds population suffers from Chronic Kidney Disease (CKD), but with no cure, how can we develop more effective therapies for this underserved population?
-
UPDATE
What is proteinuria’s role in evaluating the progression of CKD?
2022.01.25
When discussing our mouse models for chronic kidney disease (CKD), we are often asked about proteinuria as a urinary marker of kidney damage. As an important marker used in clinical trials, it's also an important endpoint to look at in non-clinical research as well.
-
UPDATE
What is the relationship between NASH and Liver Cancer?
2022.01.18
You may know that liver cancer is one of the most prevalent cancers, but do you know about its relationship with nonalcoholic steatohepatitis (NASH), which is rapidly increasing as a liver disease?
-
UPCOMING EVENTS
SMC attend BIO Partnering at JPM Week!
2022.01.10
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering event next week from Monday, January 10th to Friday, January 14th.
-
UPDATE
2021.12.17
COVID-19 is a virus belonging to the beta-coronavirus class, similar to the virus that causes severe acute respiratory syndrome (SARS). It has been reported that fibrosis could begin to be observed several weeks after infection during the SARS epidemic.
-
NEWS RELEASE
2021.11.24
Marvel Biosciences, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.